RECEIVED CENTRAL FAX CENTER

DEC-04-2007 17:12

The Webb Law Firm

DEC 0 4 2007

P.003

PTO/SB/08a (05-07)

Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Orlice; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10056680		
	Filing Date		2002-01-25		
	First Named Inventor	First Named Inventor Teddy Kosoglou			
	Art Unit		1617		
	Examiner Name	San N	San Ming R. Hui		
	Attorney Docket Numb	er	CV 01492KUS (4686-045551)		

		4.7		U.S.	PATENTS	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					·
If you wisl	h to ac	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030119809		2003-06-26	Davis, Harry R.	
	2	20030119808		2003-06-26	Lebeaut, Alexandre P., et al.	
	3	20030119757		2003-06-26	Davis, Harry R.	
	4	20030053981		2003-03-20	Davis, Harry R. et al.	,
	5	20020183305		2002-12-05	Davis, Harry R. et al.	

The Webb Law Firm

INFORMA	TION D	SCL	OSURE
STATEME	NT BY	APP	LICANT

(Not for submission under 37 CFR 1.99)

DD LILM DD CO			1.004			
Application Number		10056680				
Filing Date		2002-01-25				
First Named Inventor	Ted	dy Kosoglou				
Art Unit		1617				
Examiner Name	San	San Ming R. Hui				
Attorney Docket Number		CV 01492KUS (4688-045551)				

					,		•			
	6	20020169134	2002-11-14		Davis, Harry R.					
	7	20030109442	2003-06-12		Bisgaìer, Charl	les L., et al.				
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Add	d butto	on.	
				FOREIG	3N PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TE
	1						·			
If you wis	h to ac	d additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	butto	n	
			NON	I-PATE	NY LITE	RATURE DO	CUMENTS			
Examiner Initials*	Cite No	'' I /hook, manazine, journal, senal, symbosium, catalog, etc), date, bades(s), yolume-issue humber(s),							T 5	
	1	HAROLD BAYS, ET AL., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Export Opin, Pharmacother., Vol. 4, No. 11, pp. 1901-1938, (2003).								
	2	CESARE R. SIRTORI, "New Targets For Lipid Lowering And Atherosclerosis Prevention", Pharmac. Ther. Vol. 67, No. 3, pp. 433-447, (1995).								
	3	SANJAY KAUL, ET AL., "Intramural Delivery of Recombinant Apolipoprotein A-IMilano/Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries", Circulation Vol. 107, pp. 2551-2554, (May 12, 2003).								
	4	GIULIA CHIESA, ET AL., "Apolipoprotein A-IMilano: Current Perspectives"; Curr. Opin. Lipidol, Vol. 14, pp. 159-163, (2003).								

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

· · · · · · · · · · · · · · · · · · ·			
Application Number		10056680	
Filing Date		2002-01-25	RECEIVED
First Named Inventor Teddy		dy Kosoglou	CENTRAL FAX CENTER
Art Unit		1617	DEC-0-4-2007
Examiner Name	San	Ming R. Hui	DEO-0 1 2001
Attorney Docket Number		CV 01492KUS (46	86-045551)

	5	JOHN KASTELEIN, "What Future For Combination Therapies?", IJCP, pp. 45-50, (March 2003).						
	6	MARC EVANS, ET AL., "The Future Direction Of Cholesterol-Lowering Therapy"; Curr. Opin. Lipidol, Vol. 13, pp. [63-669, (2002).						
	7	CRAIG W. SPELLMAN, "Management of Diabetes In the Real World: Tight Control Of Glucose Metabolism", JAOA, Supplement 5, Vol. 103, No. 8, (August, 2003).						
	8	ROBERT J. LIPSY, ET AL., "Optimizing Dyslipidemia Outcomes: A Novel Pharmacotherapeutic Pathway", JMCP, Vol. 9, No. 1, (January/February 2003).						
	9	PEDRO (GLESIAS, ET Al, "New Drugs For The Treatment Of Hypercholesterolaemia", Expert Opin, Investig. Drugs, Vol. 12, No. 11, pp. 1777-1789, (2003).						
If you wis	h to a	additional non-patent literature document citation information please click the Add button						
	<u> </u>	EXAMINER SIGNATURE						
Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
¹ Soo Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language translation is attached.								